Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?

Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.